NASDAQ$IGMS
IGM Biosciences Inc · Q3 2018 earnings
Q3 2018 earnings · · Investor relations
Headline financials
Revenue & EPS history
IGM Biosciences · Revenue · Quarterly
$144M
Q2 2025+11,353.2%vs Q2 2024
Revenue by segment
IGM Biosciences · $2.68M total across 1 segment · Q4 2024
- Collaboration Revenue$2.68M—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
+4.2%
Avg return
Earnings day
-6.5%
Avg return
5 days after
-4.3%
Avg return
30 days after
58%
14 / 24 earnings
Positive
+72.4%
Q4 2021
Best reaction
-20.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.0% | +0.8% | — | |
| Q1 2025 | +4.2% | +1.7% | +3.4% | |
| Q4 2024 | -2.4% | -8.0% | +5.6% | |
| Q3 2024 | -10.4% | -21.9% | -27.9% | |
| Q2 2024 | +4.4% | +7.8% | +38.5% | |
| Q1 2024 | +1.9% | -7.2% | -17.3% | |
| Q4 2023 | +2.4% | -18.5% | -28.1% | |
| Q3 2023 | +7.3% | — | — | |
| Q2 2023 | -7.1% | — | — | |
| Q1 2023 | +6.7% | — | — | |
| Q4 2022 | -20.4% | — | — | |
| Q3 2022 | -9.9% | — | — | |
| Q2 2022 | +22.2% | — | — | |
| Q1 2022 | -7.5% | — | — | |
| Q4 2021 | +72.4% | — | — | |
| Q3 2021 | +15.9% | — | — | |
| Q2 2021 | +8.9% | — | — | |
| Q1 2021 | +10.9% | — | — | |
| Q4 2020 | +4.1% | — | — | |
| Q3 2020 | -4.2% | — | — | |
| Q2 2020 | -4.2% | — | — | |
| Q1 2020 | +5.6% | — | — | |
| Q4 2019 | -1.8% | — | — | |
| Q3 2019 | +1.2% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro